Literature DB >> 31898980

Corrigendum to "Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma" [Cancer Treatm. Rev. 82 (2019) 101946].

Arndt Vogel1, Anna Saborowski2.   

Abstract

Entities:  

Year:  2019        PMID： 31898980     DOI： 10.1016/j.ctrv.2019.101962

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  2 in total

1.  Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.

Authors:  Tiago de Castro; Leonie S Jochheim; Melanie Bathon; Sabrina Welland; Bernhard Scheiner; Kateryna Shmanko; Daniel Roessler; Najib Ben Khaled; Matthias Jeschke; Johannes M Ludwig; Jens U Marquardt; Arndt Weinmann; Matthias Pinter; Christian M Lange; Arndt Vogel; Anna Saborowski
Journal:  Ther Adv Med Oncol       Date:  2022-02-26       Impact factor: 5.485

Review 2.  Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.

Authors:  Zhi Zeng; Qiliang Lu; Yang Liu; Junjun Zhao; Qian Zhang; Linjun Hu; Zhan Shi; Yifeng Tu; Zunqiang Xiao; Qiuran Xu; Dongsheng Huang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.